References Cited in Appendix E

1.

Golmia A, Grinblat B, Finger E, et al. The development of erythema elevatum diutinum in a patient with juvenile idiopathic arthritis under treatment with abatacept. Clin Rheumatol. 2008;27(1):105–6. [PubMed: 17932616]

2.

Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–91. [PubMed: 18632147]

3.

Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68(12):1863–9. [PMC free article: PMC2770105] [PubMed: 19147611]

4.

Cimaz R, Gana S, Braccesi G, et al. Sydenham's chorea in a girl with juvenile idiopathic arthritis treated with anti-TNF(alpha) therapy. Mov Disord. 2010;25(4):511–4. [PubMed: 20014056]

5.

Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–20. [PubMed: 18716298]

6.

Canna S, Frankovich J, Higgins G, et al. Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist. Pediatric Rheumatology. 2009:7. [PMC free article: PMC2805658] [PubMed: 20028520]

7.

Ilowite N, Porras O, Reiff A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol. 2009;28(2):129–37. [PubMed: 18766426]

8.

Kone-Paut I, Retornaz K, Garnier JM, et al. Visceral leishmaniasis in a patient with systemic juvenile arthritis treated by IL-1RA agonist (Anakinra). Clin Exp Rheumatol. 2007;25(1):119. [PubMed: 17418007]

9.

Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67(3):302–8. [PubMed: 17947302]

10.

Ohlsson V, Baildam E, Foster H, et al. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford). 2008;47(4):555–6. [PubMed: 18321945]

11.

Zeft A, Hollister R, LaFleur B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol. 2009;15(4):161–4. [PubMed: 19363453]

12.

Bloom BJ. Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000;43(11):2606–8. [PubMed: 11083287]

13.

Bout-Tabaku S, Rivas-Chacon R, Restrepo R. Systemic lupus erythematosus in a patient treated with etanercept for polyarticular juvenile rheumatoid arthritis. J Rheumatol. 2007;34(12):2503–4. [PubMed: 18061971]

14.

Dallocchio A, Canioni D, Ruemmele F, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: A French retrospective study. Rheumatology (Oxford). 2010;49(9):1694–8. [PubMed: 20472717]

15.

Elwood RL, Pelszynski MM, Corman LI. Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept. Pediatr Infect Dis J. 2003;22(3):286–8. [PubMed: 12664882]

16.

Fathalla BM, Goldsmith DP, Pascasio JM, et al. Development of autoimmune hepatitis in a child with systemic-onset juvenile idiopathic arthritis during therapy with etanercept. J Clin Rheumatol. 2008;14(5):297–8. [PubMed: 18824922]

17.

Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(9):2794–804. [PubMed: 19714630]

18.

Horneff G, Ebert A, Fitter S, et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology (Oxford). 2009;48(8):916–9. [PubMed: 19483091]

19.

Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68(4):519–25. [PubMed: 18413440]

20.

Hung JJ, Huang JL. Etanercept therapy in children with juvenile rheumatoid arthritis. J Microbiol Immunol Infect. 2005;38(6):444–6. [PubMed: 16341346]

21.

Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2005;32(5):935–42. [PubMed: 15868633]

22.

Kunzmann S, Warmuth-Metz M, Girschick HJ. Cerebral demyelination in association with TNF-inhibition therapy in a 5-year-old girl with aseptic meningitis as the first symptom of Still's disease. Scand J Rheumatol. 2005;34(1):76–8. [PubMed: 15903034]

23.

Lepore L, Marchetti F, Facchini S, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2003;21(2):276–7. [PubMed: 12747299]

24.

Livermore PA, Murray KJ. Anti-tumour necrosis factor therapy associated with cutaneous vasculitis. Rheumatology (Oxford). 2002;41(12):1450–2. [PubMed: 12468829]

25.

Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342(11):763–9. [PubMed: 10717011]

26.

Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003;48(1):218–26. [PubMed: 12528122]

27.

Mangge H, Gindl S, Kenzian H, et al. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2003;30(11):2506–7. [PubMed: 14677200]

28.

Mene P, Franeta AJ, Conti G, et al. Extracapillary glomerulonephritis during etanercept treatment for juvenile psoriatic arthritis. Clin Exp Rheumatol. 2010;28(1):91–3. [PubMed: 20346246]

29.

Mori M, Takei S, Imagawa T, et al. Pharmacokinetics, efficacy, and safety of short-term (12 weeks) etanercept for methotrexate-refractory polyarticular juvenile idiopathic arthritis in Japan. Modern Rheumatology. 2005;15(6):397–404. [PubMed: 17029102]

30.

Morishita K, Petty R, Cairns R, et al. Serious musculoskeletal infections in children receiving anti-tumor necrosis factor-alpha therapy: a case series. Clin Rheumatol. 2010;29(6):677–81. [PubMed: 20383549]

31.

Peek R, Scott-Jupp R, Strike H, et al. Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann Rheum Dis. 2006;65(9):1259. [PMC free article: PMC1798298] [PubMed: 16905590]

32.

Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68(5):635–41. [PubMed: 18413443]

33.

Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48(4):1093–101. [PubMed: 12687553]

34.

Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2003;30(2):401–3. [PubMed: 12563702]

35.

Robinson RF, Nahata MC, Hayes JR, et al. Quality-of-life measurements in juvenile rheumatoid arthritis patients treated with etanercept. Clinical Drug Investigation. 2003;23(8):511–8. [PubMed: 17535063]

36.

Skytta E, Pohjankoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2000;18(4):533–4. [PubMed: 10949736]

37.

Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53(1):18–23. [PubMed: 15696578]

38.

Takei S, Groh D, Bernstein B, et al. Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis. J Rheumatol. 2001;28(7):1677–80. [PubMed: 11469478]

39.

Tauber T, Daniel D, Barash J, et al. Optic neuritis associated with etanercept therapy in two patients with extended oligoarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2005;44(3):405. [PubMed: 15637094]

40.

Tauber T, Turetz J, Barash J, et al. Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS. 2006;10(1):26–9. [PubMed: 16527676]

41.

Tynjala P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(4):548–50. [PMC free article: PMC1856052] [PubMed: 17068061]

42.

Tzaribachev N, Kuemmerle-Deschner J, Eichner M, et al. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years. Rheumatol Int. 2008;28(10):1031–4. [PubMed: 18369626]

43.

Wiegering V, Morbach H, Dick A, et al. Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: A case report and review of the literature. Rheumatol Int. 2010;30(6):801–4. [PubMed: 19506877]

44.

Aikawa NE, Carvalho JF, Bonfa E, et al. Macrophage activation syndrome associated with etanercept in a child with systemic onset juvenile idiopathic arthritis. Israel Medical Association Journal. 2009;11(10):635–6. [PubMed: 20077954]

45.

Billiau AD, Loop M, Le PQ, et al. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology (Oxford). 2010;49(8):1550–8. [PubMed: 20444859]

46.

Fitch PG, Cron RQ. Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-alpha. J Rheumatol. 2006;33(4):825. author reply 6-7. [PubMed: 16583487]

47.

Holl-Wieden A, Beer M, Marx A, et al. Infection of an urachal cyst during etanercept therapy in juvenile idiopathic arthritis. Rheumatol Int. 2008;28(8):819–22. [PubMed: 18193232]

48.

Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(12):1638–44. [PMC free article: PMC1754849] [PubMed: 15115709]

49.

Kuemmerle-Deschner JB, Horneff G. Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis. Rheumatol Int. 2007;28(2):153–6. [PubMed: 17641897]

50.

Yildirim-Toruner C, Kimura Y, Rabinovich E. Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis. J Rheumatol. 2008;35(8):1680–1. [PubMed: 18671328]

51.

Aggarwal A, Agarwal V, Danda D, et al. Outcome in juvenile rheumatoid arthritis in India. Indian Pediatr. 2004;41(2):180–4. [PubMed: 15004305]

52.

de Castro TC, Terreri MT, Len C, et al. Treatment of refractory juvenile idiopathic arthritis via pulse therapy using methylprednisolone and cyclophosphamide. Sao Paulo Med J. 2003;121(3):117–20. [PubMed: 12920473]

53.

Prieur AM, Adleff A, Debre M, et al. High dose immunoglobulin therapy in severe juvenile chronic arthritis: Long-term follow-up in 16 patients. Clin Exp Rheumatol. 1990;8(6):603–9. [PubMed: 2289332]

54.

Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol. 1994;21(12):2353–8. [PubMed: 7699642]

55.

Uziel Y, Laxer RM, Schneider R, et al. Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a followup study. J Rheumatol. 1996;23(5):910–8. [PubMed: 8724308]

56.

Armbrust W, Kamphuis SS, Wolfs TW, et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2004;43(4):527–9. [PubMed: 15024141]

57.

Becker M, Rose CD, McIlvain-Simpson G. Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis. J Rheumatol. 2004;31(12):2529–30. [PubMed: 15570667]

58.

Corona F, Scarazatti M, Dell'Era L, et al. Active refractory juvenile idiopathic arthritis: Treatment with infliximab. Efficacy and safety. Italian Journal of Pediatrics. 2004;30(3):165–8.

59.

Billiau AD, Cornillie F, Wouters C. Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children. J Rheumatol. 2002;29(5):1111–4. [PubMed: 12022340]

60.

Katsicas MM, Russo RA. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept. Clin Exp Rheumatol. 2005;23(4):545–8. [PubMed: 16095128]

61.

Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis. 2003;62(3):245–7. [PMC free article: PMC1754468] [PubMed: 12594111]

62.

Mangge H, Heinzl B, Grubbauer HM, et al. Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int. 2003;23(5):258–61. [PubMed: 12687288]

63.

Pipitone MA, Adams B, Sheth A, et al. Crusted scabies in a patient being treated with infliximab for juvenile rheumatoid arthritis. J Am Acad Dermatol. 2005;52(4):719–20. [PubMed: 15793541]

64.

Simonini G, Zannin ME, Caputo R, et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology (Oxford). 2008;47(10):1510–4. [PubMed: 18676502]

65.

Tutar E, Ekici F, Nacar N, et al. Delayed maculopapular, urticarial rash due to infliximab in two children with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford). 2004;43(5):674–5. [PubMed: 15103034]

66.

Tyler LN, Harville TO, Blackall DP. Multiple alloantibodies after transfusion in an infant treated with infliximab. N Engl J Med. 2007;357(20):2092–3. discussion 3. [PubMed: 18003972]

67.

Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096–106. [PubMed: 17763439]

68.

Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: Findings from an open-label treatment extension. Ann Rheum Dis. 2010;69(4):718–22. [PMC free article: PMC2946101] [PubMed: 20237125]

69.

Foeldvari I, Wierk A. Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. J Rheumatol. 2010;37(8):1763–7. [PubMed: 20472925]

70.

Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352(16):1655–66. [PubMed: 15843668]

71.

Silverman E, Spiegel L, Hawkins D, et al. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2005;52(2):554–62. [PubMed: 15693001]

72.

Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7(6):R1281–8. [PMC free article: PMC1297576] [PubMed: 16277681]

73.

Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998–1006. [PubMed: 18358927]

74.

Kvien TK, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol. 1986;13(1):118–23. [PubMed: 3517321]

75.

Lin YT, Yang YH, Tsai MJ, et al. Long-term effects of azathioprine therapy for juvenile rheumatoid arthritis. J Formos Med Assoc. 2000;99(4):330–5. [PubMed: 10870318]

76.

Savolainen HA, Kautiainen H, Isomaki H, et al. Azathioprine in patients with juvenile chronic arthritis: a longterm followup study. J Rheumatol. 1997;24(12):2444–50. [PubMed: 9415656]

77.

Gattinara M, Lomater C, Gerloni V, et al. Cyclosporin in pediatric rheumatology; a seven years experience. Acta Univ Carol Med (Praha). 1994;40(1-4):105–8. [PubMed: 9355683]

78.

Gerloni V, Cimaz R, Gattinara M, et al. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford). 2001;40(8):907–13. [PubMed: 11511760]

79.

Krugmann J, Sailer-Hock M, Muller T, et al. Epstein-Barr virus-associated Hodgkin's lymphoma and legionella pneumophila infection complicating treatment of juvenile rheumatoid arthritis with methotrexate and cyclosporine A. Hum Pathol. 2000;31(2):253–5. [PubMed: 10685644]

80.

Mateicka F, Lukac J, Rovensky J, et al. Cyclosporin A in treatment of juvenile chronic arthritis: Preliminary results with Consupren(registered trademark). International Journal of Immunotherapy. 1994;10(1):11–4.

81.

Murphy EA, Morris AJ, Walker E, et al. Cyclosporine A induced colitis and acquired selective IgA deficiency in a patient with juvenile chronic arthritis. J Rheumatol. 1993;20(8):1397–8. [PubMed: 8230025]

82.

Ostensen M, Hoyeraal HM, Kass E. Tolerance of cyclosporine A in children with refractory juvenile rheumatoid arthritis. J Rheumatol. 1988;15(10):1536–8. [PubMed: 3204600]

83.

Pistoia V, Buoncompagni A, Scribanis R, et al. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study. Clin Exp Rheumatol. 1993;11(2):203–8. [PubMed: 8508564]

84.

Ruperto N, Ravelli A, Castell E, et al. Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol. 2006;24(5):599–605. [PubMed: 17181934]

85.

Ravelli A, Moretti C, Temporini F, et al. Combination therapy with methotrexate and cyclosporine A in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002;20(4):569–72. [PubMed: 12175118]

86.

Kvien TK, Hoyeraal HM, Sandstad B. Gold sodium thiomalate and D-penicillamine. A controlled, comparative study in patients with pauciarticular and polyarticular juvenile rheumatoid arthritis. Scand J Rheumatol. 1985;14(4):346–54. [PubMed: 3936167]

87.

Prieur AM, Piussan C, Manigne P, et al. Evaluation of D-penicillamine in juvenile chronic arthritis. A double-blind, multicenter study. Arthritis Rheum. 1985;28(4):376–82. [PubMed: 3885958]

88.

Sahn EE, Maize JC, Garen PD, et al. D-penicillamine-induced elastosis perforans serpiginosa in a child with juvenile rheumatoid arthritis. Report of a case and review of the literature. J Am Acad Dermatol. 1989;20(5 Pt 2):979–88. [PubMed: 2523911]

89.

Brewer EJ, Giannini EH, Kuzmina N, et al. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. N Engl J Med. 1986;314(20):1269–76. [PubMed: 3517643]

90.

Kvien TK, Hoyeraal HM, Sandstad B. Slow acting antirheumatic drugs in patients with juvenile rheumatoid arthritis--evaluated in a randomized, parallel 50-week clinical trial. J Rheumatol. 1985;12(3):533–9. [PubMed: 3930720]

91.

Swartz MO, Silver RM. D-penicillamine induced polymyositis in juvenile chronic arthritis: report of a case. J Rheumatol. 1984;11(2):251–2. [PubMed: 6726729]

92.

Arakawa H, Yamasaki M, Kurihara Y, et al. Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imaging. 2003;18(4):231–6. [PubMed: 14561908]

93.

Becker ML, Rose CD, Cron RQ, et al. Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: Comparison of 2 initial dosing regimens. J Rheumatol. 2010;37(4):870–5. [PMC free article: PMC2893572] [PubMed: 20194449]

94.

Chedeville G, Quartier P, Miranda M, et al. Improvements in growth parameters in children with juvenile idiopathic arthritis associated with the effect of methotrexate on disease activity. Joint Bone Spine. 2005;72(5):392–6. [PubMed: 16087383]

95.

Cleary AG, McDowell H, Sills JA. Polyarticular juvenile idiopathic arthritis treated with methotrexate complicated by the development of non-Hodgkin's lymphoma. Arch Dis Child. 2002;86(1):47–9. [PMC free article: PMC1719052] [PubMed: 11806884]

96.

Corona F, Bardare M, Cimaz R, et al. Methotrexate in juvenile chronic arthritis. Clin Exp Rheumatol. 1993;11(3):346–7. [PubMed: 8353993]

97.

Cron RQ, Sherry DD, Wallace CA. Methotrexate-induced hypersensitivity pneumonitis in a child with juvenile rheumatoid arthritis. J Pediatr. 1998;132(5):901–2. [PubMed: 9602213]

98.

Douglas Graham L, Myones BL, Rivas-Chacon RF, et al. Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr. 1992;120(3):468–73. [PubMed: 1538301]

99.

Falcini F, Taccetti G, Ermini M, et al. Methotrexate-associated appearance and rapid progression of rheumatoid nodules in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 1997;40(1):175–8. [PubMed: 9008613]

100.

Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med. 1992;326(16):1043–9. [PubMed: 1549149]

101.

Gottlieb BS, Keenan GF, Lu T, et al. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics. 1997;100(6):994–7. [PubMed: 9374571]

102.

Graham LD, Myones BL, Rivas-Chacon RF, et al. Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr. 1992;120(3):468–73. [PubMed: 1538301]

103.

Halle F, Prieur AM. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol. 1991;9(3):297–302. [PubMed: 1879091]

104.

Huang JL. Methotrexate in the treatment of children with chronic arthritis--long-term observations of efficacy and safety. Br J Clin Pract. 1996;50(6):311–4. [PubMed: 8983319]

105.

Hunstad DA, French AR. Histoplasmosis in a child with JRA on low-dose methotrexate. Rheumatology (Oxford). 2007;46(1):177–8. [PubMed: 17114804]

106.

Keim D, Ragsdale C, Heidelberger K, et al. Hepatic fibrosis with the use of methotrexate for juvenile rheumatoid arthritis. J Rheumatol. 1990;17(6):846–8. [PubMed: 2388211]

107.

Lee PPW, Lee TL, Wong WHS, et al. The use of methotrexate in juvenile idiopathic arthritis: A single center experience. Hong Kong Journal of Paediatrics. 2006;11(3):191–8+263.

108.

Lee SL, Neskey D, Mouzakes J. Potential predisposition for nasal septal perforation with methotrexate use: report of 2 cases and literature review. Ear Nose Throat J. 2009;88(8):E12–4. [PubMed: 19688702]

109.

Lin YT, Tsai MJ, Wang LH, et al. Efficacy and safety of methotrexate therapy for juvenile rheumatoid arthritis. J Formos Med Assoc. 2000;99(8):623–9. [PubMed: 10969505]

110.

Londino AV Jr, Blatt J, Knisely AS. Hodgkin's disease in a patient with juvenile rheumatoid arthritis taking weekly low dose methotrexate. J Rheumatol. 1998;25(6):1245–6. [PubMed: 9632099]

111.

Martini A, Ravelli A, Viola S, et al. Methotrexate hepatotoxic effects in children with juvenile rheumatoid arthritis. J Pediatr. 1991;119(2):333–4. [PubMed: 1861227]

112.

Muzaffer MA, Schneider R, Cameron BJ, et al. Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr. 1996;128(5 Pt 1):698–700. [PubMed: 8627446]

113.

Ortiz-Alvarez O, Morishita K, Avery G, et al. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol. 2004;31(12):2501–6. [PubMed: 15570658]

114.

Padeh S, Sharon N, Schiby G, et al. Hodgkin's lymphoma in systemic onset juvenile rheumatoid arthritis after treatment with low dose methotrexate. J Rheumatol. 1997;24(10):2035–7. [PubMed: 9330950]

115.

Ravelli A, De Benedetti F, Viola S, et al. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr. 1996;128(2):275–8. [PubMed: 8636829]

116.

Ravelli A, Gerloni V, Corona F, et al. Oral versus intramuscular methotrexate in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. Clin Exp Rheumatol. 1998;16(2):181–3. [PubMed: 9536397]

117.

Ravelli A, Caria MC, Buratti S, et al. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2001;28(4):865–7. [PubMed: 11327264]

118.

Riddle R, Ryser CN, Morton AA, et al. The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis. J Pediatr Psychol. 2006;31(3):262–71. [PubMed: 15872147]

119.

Rose CD, Singsen BH, Eichenfield AH, et al. Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr. 1990;117(4):653–9. [PubMed: 2213397]

120.

Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004;50(7):2191–201. [PubMed: 15248217]

121.

Russo RA, Katsicas MM. Tolerance of parenteral, higher dose methotrexate in children with juvenile chronic arthritis. Clin Exp Rheumatol. 2000;18(3):425. [PubMed: 10895392]

122.

Savolainen HA, Leirisalo-Repo M. Eosinophilia as a side-effect of methotrexate in patients with chronic arthritis. Clin Rheumatol. 2001;20(6):432–4. [PubMed: 11771529]

123.

Schmeling H, Biber D, Heins S, et al. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis. J Rheumatol. 2005;32(9):1832–6. [PubMed: 16142884]

124.

Speckmaier M, Findeisen J, Woo P, et al. Low-dose methotrexate in systemic onset juvenile chronic arthritis. Clin Exp Rheumatol. 1989;7(6):647–50. [PubMed: 2612084]

125.

Takeyama J, Sato A, Nakano K, et al. Epstein-Barr virus associated Hodgkin lymphoma in a 9-year-old girl receiving long-term methotrexate therapy for juvenile idiopathic arthritis. J Pediatr Hematol Oncol. 2006;28(9):622–4. [PubMed: 17006270]

126.

Truckenbrodt H, Hafner R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum. 1986;29(6):801–7. [PubMed: 3718568]

127.

van der Meer A, Wulffraat NM, Prakken BJ, et al. Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol. 2007;25(3):480–5. [PubMed: 17631750]

128.

Wallace CA, Sherry DD. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol. 1992;19(10):1604–7. [PubMed: 1464876]

129.

Yildirim Y. Primary ovarian large B-cell lymphoma in patient with juvenile rheumatoid arthritis treated with low dose Methotrexate. Gynecol Oncol. 2005;97(1):249–52. [PubMed: 15790469]

130.

Kocharla L, Taylor J, Weiler T, et al. Monitoring methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol. 2009;36(12):2813–8. [PubMed: 19918032]

131.

Balci DD, Peker E, Duran N, et al. Sulfasalazine-induced hypersensitivity syndrome in a 15-year-old boy associated with human herpesvirus-6 reactivation. Cutan Ocul Toxicol. 2009;28(1):45–7. [PubMed: 19514926]

132.

Burgos-Vargas R, Vazquez-Mellado J, Pacheco-Tena C, et al. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis. 2002;61(10):941–2. [PMC free article: PMC1753917] [PubMed: 12228171]

133.

Chen CC, Lin YT, Yang YH, et al. Sulfasalazine therapy for juvenile rheumatoid arthritis. J Formos Med Assoc. 2002;101(2):110–6. [PubMed: 12099201]

134.

Hertzberger-ten Cate R, Cats A. Toxicity of sulfasalazine in systemic juvenile chronic arthritis. Clin Exp Rheumatol. 1991;9(1):85–8. [PubMed: 1675939]

135.

Imundo LF, Jacobs JC. Sulfasalazine therapy for juvenile rheumatoid arthritis. J Rheumatol. 1996;23(2):360–6. [PubMed: 8882047]

136.

Joos R, Veys EM, Mielants H, et al. Sulfasalazine treatment in juvenile chronic arthritis: an open study. J Rheumatol. 1991;18(6):880–4. [PubMed: 1680193]

137.

van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum. 1998;41(5):808–16. [PubMed: 9588731]

138.

van Rossum MA, van Soesbergen RM, Boers M, et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis. 2007;66(11):1518–24. [PMC free article: PMC2111611] [PubMed: 17491099]

139.

Ansell BM, Hall MA, Loftus JK, et al. A multicentre pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol. 1991;9(2):201–3. [PubMed: 1676352]

140.

Gedalia A, Barash J, Press J, et al. Sulphasalazine in the treatment of pauciarticular-onset juvenile chronic arthritis. Clin Rheumatol. 1993;12(4):511–4. [PubMed: 7907286]

141.

Gunnarsson I, Kanerud L, Pettersson E, et al. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol. 1997;36(10):1089–94. [PubMed: 9374926]

142.

Huang JL, Chen LC. Sulphasalazine in the treatment of children with chronic arthritis. Clin Rheumatol. 1998;17(5):359–63. [PubMed: 9805178]

143.

Huang JL, Hung IJ, Chen LC, et al. Successfully treated sulphasalazine-induced fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia with intravenous immunoglobulin. Clin Rheumatol. 1998;17(4):349–52. [PubMed: 9776124]

144.

Kummerle-Deschner J, Dannecker G. Sulphasalazine desensitization in a paediatric patient with juvenile chronic arthritis. Acta Paediatr. 1995;84(8):952–4. [PubMed: 7488828]

145.

Ozdogan H, Turunc M, Deringol B, et al. Sulphasalazine in the treatment of juvenile rheumatoid arthritis: a preliminary open trial. J Rheumatol. 1986;13(1):124–5. [PubMed: 2871188]

146.

Pinana E, Lei SH, Merino R, et al. DRESS-syndrome on sulfasalazine and naproxen treatment for juvenile idiopathic arthritis and reactivation of human herpevirus 6 in an 11-year-old caucasian boy. J Clin Pharm Ther. 2010;35(3):365–70. [PubMed: 20831538]

147.

Settas L, Alexiou P, Dimitriadis G, et al. Effect of sulphasalazine in patients with juvenile chronic arthritis (JCA). Acta Univ Carol Med (Praha). 1991;37(1-2):76–9. [PubMed: 1688267]

148.

Varbanova BB, Dyankov ED. Sulphasalazine. An alternative drug for second-line treatment of juvenile chronic arthritis. Adv Exp Med Biol. 1999;455:331–6. [PubMed: 10599365]

149.

Flato B, Vinje O, Forre O. Toxicity of antirheumatic and anti-inflammatory drugs in children. Clin Rheumatol. 1998;17(6):505–10. [PubMed: 9890680]

150.

Lomater G, Gattinara M, Gerloni V, et al. Combination therapy of juvenile rheumatoid arthritis with hydroxychloroquine-gold-methotrexate: a pilot study. Acta Univ Carol Med (Praha). 1994;40(1-4):109–12. [PubMed: 9355684]

151.

Barash J, Cooper M, Tauber Z. Hepatic, cutaneous and hematologic manifestations in juvenile chronic arthritis. Clin Exp Rheumatol. 1991;9(5):541–3. [PubMed: 1954707]